Literature DB >> 25284608

Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.

Xiaoxian Zhao1, Juraj Bodo, Danyu Sun, Lisa Durkin, Jeffrey Lin, Mitchell R Smith, Eric D Hsi.   

Abstract

Entities:  

Keywords:  BCL-2; Bruton tyrosine kinase; apoptosis; mantle cell lymphoma; synergy

Mesh：

Substances：

Year:  2014        PMID： 25284608     DOI： 10.1111/bjh.13149

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  36 in total

Review 1.  Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Authors:  Deborah M Stephens; Stephen E Spurgeon
Journal:  Ther Adv Hematol       Date:  2015-10

Review 2.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

3.  Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series.

Authors:  Alberto Fabbri; Emanuele Cencini; Angela Giovanna Congiu; Maurizio Miglino; Luigi Rigacci; Monica Bocchia
Journal:  Am J Blood Res       Date:  2020-12-15

Review 4.  Cell Death Pathways in Lymphoid Malignancies.

Authors:  Luke Fletcher; Edward Nabrinsky; Tingting Liu; Alexey Danilov
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

Review 5.  Novel agents in mantle cell lymphoma.

Authors:  Anita Kumar
Journal:  Curr Oncol Rep       Date:  2015-08       Impact factor: 5.075

6.  CCMCL1: a new model of aggressive mantle cell lymphoma.

Authors:  Xiaoxian Zhao; Selina Chen-Kiang; Shashirekha Shetty; Maurizio Di Liberto; Juraj Bodo; Lisa Durkin; Ken Eng; Olivier Elemento; Mitchell R Smith; Eric D Hsi
Journal:  Blood       Date:  2015-04-23       Impact factor: 22.113

7.  Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.

Authors:  S Peirs; V Frismantas; F Matthijssens; W Van Loocke; T Pieters; N Vandamme; B Lintermans; M P Dobay; G Berx; B Poppe; S Goossens; B C Bornhauser; J-P Bourquin; P Van Vlierberghe
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

8.  Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Fabiola Cervantes-Gomez; Betty Lamothe; Jennifer A Woyach; William G Wierda; Michael J Keating; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

Review 9.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

Review 10.  Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.

Authors:  Allison Rosenthal
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.